Bicycle Therapeutics plc filings document a clinical-stage pharmaceutical issuer whose Nasdaq-listed ADSs each represent one ordinary share. The company’s 8-K reports furnish quarterly and annual financial results, business highlights, program updates for nuzefatide pevedotin and the EphA2 pipeline, and leadership and board changes.
Proxy materials cover annual general meeting matters, director elections, executive compensation, equity awards, and shareholder voting procedures for the England and Wales company. The filings also identify the ordinary share and ADS registration structure, Nasdaq listing context, governance arrangements, and material-event disclosures tied to the company’s Bicycle technology and oncology pipeline.
Bicycle Therapeutics plc (BCYC) Chief Operating Officer Jennifer Scott Perry reported direct sales of 30 ordinary shares on October 5, 2026, at a weighted average price of $3.57 per share; prices ranged from $3.56 to $3.57. The sale was required to cover statutory tax withholding tied to RSU vesting and settlement. She also reported selling 326 ordinary shares at $3.78 per share on October 5, 2026, under a Rule 10b5-1 trading plan.
Bicycle Therapeutics plc director Robert Charles Swanton reported selling 3,431 ordinary shares on October 2, 2026, at a weighted average price of $3.47 per share. The shares were sold to cover statutory tax withholding related to RSU vesting and settlement, as required by his award agreement; the transaction was not discretionary. Swanton directly held 15,782 shares after the sale. No Rule 10b5-1 plan is reported.
Bicycle Therapeutics plc Chief Scientific Officer Michael Skynner reported direct sales of 1,942 Ordinary Shares on October 2, 2026, at a weighted average price of $3.47 per share, and 503 Ordinary Shares on October 5, 2026, at a weighted average price of $3.57 per share. The reported prices reflect transactions within ranges of $3.41 to $3.525 and $3.56 to $3.57, respectively. Both sales covered statutory tax withholding obligations tied to RSU vesting and settlement; the award agreement requires these sell-to-cover transactions, which the footnote says were not discretionary.
Bicycle Therapeutics plc (BCYC) Chief Product & Supply Chain Officer Michael Charles Ferguson Hannay reported two sell-to-cover transactions: 1,572 ordinary shares on October 2, 2026, at a weighted average price of $3.47 per share, and 242 shares on October 5, 2026, at a weighted average price of $3.57 per share. Both transactions were required by his award agreement to cover statutory tax withholding tied to RSU vesting and settlement, rather than being discretionary sales. The October 2 shares sold at prices from $3.41 to $3.525; the October 5 shares sold at prices from $3.56 to $3.57.
Bicycle Therapeutics plc (BCYC) Chief Operating Officer Jennifer Scott Perry reported sales of 1,500 ordinary shares on October 2 and October 5, 2026. She sold 1,094 shares on October 2 at a weighted average price of $3.47 per share, and on October 5 sold 80 shares at a weighted average of $3.56 and 326 shares at $3.78.
The 1,094- and 80-share sales covered statutory tax withholding required in connection with RSU vesting and settlement under her award agreement. The 326-share sale was made under a Rule 10b5-1 trading plan adopted March 27, 2025.
Bicycle Therapeutics plc (BCYC) chief executive officer and director Kevin Lee reported two direct sales of ordinary shares to fund statutory tax withholding on RSUs. On October 2, 2026, he sold 6,167 shares at a weighted average price of $3.47, with sale prices ranging from $3.41 to $3.525. On October 5, 2026, he sold 1,638 shares at a weighted average price of $3.57, with sale prices ranging from $3.56 to $3.57. The award agreement mandated both sell-to-cover transactions; they were not discretionary sales.
Bicycle Therapeutics plc (BCYC) Chief Financial Officer Travis Alvin Thompson reported selling 893 ordinary shares on October 2, 2026, at a weighted-average $3.47 per share, and 79 shares on October 5, 2026, at a weighted-average $3.57 per share. Both were required sell-to-cover transactions to fund minimum statutory tax withholding associated with RSU vesting and settlement under his award agreement; the footnote says they were not discretionary. No Rule 10b5-1 plan is reported.
Bicycle Therapeutics plc (BCYC) Chief Financial Officer Travis Alvin Thompson reported direct holdings of 9,074 ordinary shares as of June 22, 2023. The holdings include restricted stock unit awards: 3,094 RSUs vest in 11 equal quarterly installments beginning July 3, 2023; 5,000 RSUs vest one-fourth on January 3, 2024, with the remaining RSUs vesting in 12 equal quarterly installments thereafter.
A notice concerning Bicycle Therapeutics plc lists officer Kevin Lee's proposed sale of 9,000 common shares, with an approximate sale date of October 2, 2026, through Nasdaq; the listed aggregate market value is $31,231. The notice also includes entries for 12,512 and 3,594 common shares, each identifying restricted stock units from the issuer as equity compensation, dated October 2 and October 5, 2026.
Bicycle Therapeutics plc (BCYC) reported that on August 18, 2026, Charles Swanton resigned, effective immediately, as a Class II director on the Board of Directors, as a member of the Board’s committees, and as a member of the company’s Clinical Advisory Board. The company states that Dr. Swanton resigned for personal reasons and that his resignation was not due to any disagreement with Bicycle Therapeutics regarding its operations, policies, or practices.